Not necessarily. MPNs are complex. As far as I can tell based on the limited data, no one drug can take care of ALL. In that regard, Imetelstat might not be a competitor for JAK inhibitors, rather complement each other in some way, like Revlimid and Velcade in MM. That's my initial take, have to see more data from Imetelstat, JAK1, JAK2.
Market Data 
Markets 
AI
